Silymarin as an adjunct to glibenclamide therapy improves long-term and postprandial glycemic control and body mass index in type 2 diabetes

Journal of Medicinal Food

Volumn 10, Issue 3, 2007, Pages 543-547

  Hussain, Saad Abdul Rehman ^a  

^a UNIVERSITY OF BAGHDAD   (Iraq)

Author keywords

Postprandial glucose excursions; Silymarin; Type 2 diabetes mellitus

Indexed keywords

GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; PLACEBO; SILYMARIN;

ADD ON THERAPY; ADULT; ARTICLE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTIOXIDANTS; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FASTING; FEMALE; FOOD; GLYBURIDE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PLACEBOS; SILYMARIN;

EID: 34848881620     PISSN: 1096620X     EISSN: None     Source Type: Journal    
DOI: 10.1089/jmf.2006.089     Document Type: Article

References (30)

1. Cross CE, Halliwell B, Borish ET, et al: Oxygen radicals and human diseases. Ann Intern Med 1987;107:526-545.
2. Giugliano D, Paolisso G, Giugliano D: Oxidative stress and diabetic vascular complications. Diabetes Care 1996;19:257-267.
3. Paolisso G, Giugliano D: Oxidative stress and insulin is there a relationship. Diabetologia 1996;39:357-363.
4. Cerillo A, Giugliano D, Qutraro A, Dello R, Lefebvre P: Metabolic control may influence the increased superoxide generation in diabetic serum. Diabet Med 1991;8:540-542.
5. Aydin A, Orhan H, Sayal A, Oztan M, Sahin G, Isimer A: Oxidative stress and nitric oxide related parameters in type 2 diabetes mellitus: effects of glycemic control. Clin Biochem 2001;34:65-70.
6. Caimi G, LoPresti R, Montana M, et al: Diabetes mellitus: mean erythrocyte aggregation, glycometabolic pattern, red cells calcium content and membrane dynamic properties. Microvasc Res 1993;46:401-405.
7. Ceriello A: The emerging role post-prandial hyperglycemic spikes in the pathogenesis of diabetic complications. Diabet Med 1998;15:188-193.
8. Seghrouchni I, Drai J, Bannier E, et al: Oxidative stress parameters in type 1, type 2 and insulin-treated type 2 diabetes mellitus: insulin treatment efficiency. Clin Chem Acta 2002;321:89-96.
9. Darko D, Dorhnhorst A, Kelly F, Ritter J, Chowienczyk P: Lack of effect of oral vitamin C on blood pressure, oxidative stress and endothelial function. Clin Sci 2002;103:339-344.
10. Gutteridge JM, Halliwell B: Free radicals and antioxidants in the year 2000. Ann NY Acad Sci 2000;899:136-147.
11. Wellington K, Harvis B: Silymarin: a review of its clinical properties in the management of hepatic disorders. Biodrugs 2001;15:465-489.
12. Soto C, Peres B, Favari L, Reyes J: Prevention of alloxan-induced diabetes mellitus in rat by silymarin. Comp Biochem Physiol 1998;119:125-129.
13. Barham D, Trinder P: An improved colour reagent for the determination of blood glucose by the oxidase system. Analyst 1972;97:142-145.
14. Winterhalter KH: Determination of glycosylated hemoglobin. In: Methods in Enzymology, Vol 76 (Antonini E, Rossi BL, Chain CE, eds.), Academic Press, London, 1981, pp. 732-737.
15. st ed., W.B. Saunders, London, 2002.
16. Halliwell B: Free radicals, antioxidants and human diseases. Lancet 1994;344:721-724.
17. Nishikawa T, Edelstein D, Du XL, et al: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycemic damage. Nature 1999;404:787-790.
18. Soto C, Mena R, Luna J, et al: Silymarin induces recovery of pancreatic function after alloxan damage in rats. Life Sci 2004;75:2167-2180.
19. Ciccone M, Pestrichella V, Rossi O, et al: Oxidative stress is an early marker of endothelial dysfunction. Clin Hemorheol Microcirc 1999;21:341-342.
20. Facchini FS, Humphreys MH, DoNascimento CA, Abbasi F, Reaven GM: Relation between insulin resistance and plasma concentrations of lipid hydroperoxides, carotenoides, and tocopherols. Am J Clin Nutr 2000;72:776-779.
21. Bell KS, Schmitz-Peiffer C, Lim-Fraser M, Biden TJ, Cooney GJ, Kraegen EW: Acute reversal of lipid-induced muscle insulin resistance is associated with rapid alteration in PK-Cθ localization. Am J Physiol Endocrinol Metab 2000;279:E1196-E1201.
22. Kelly DJ, Zhang Y, Hepper C, et al: Protein kinase Cβ inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes 2003;52:512-518.
23. Bremner P, Heinrich M: Natural products as targeted modulators of the nuclear factor-κB pathways. J Pharm Pharmacol 2002;54:453-472.
24. Velussi M, Cernigoi AM, DeMonte A, Papas F, Caffau C, Zilli M: Long-term treatment with an antioxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and MDA levels in cirrhotic diabetic patients. J Hepatol 1997;26:871-879.
25. Purnell JQ, Weyer C: Weight effect of current and experimental diabetes drugs: from promotion to alleviation of obesity. Treatments Endocrinol 2003;21:23-37.
26. American Diabetes Association: Post-prandial blood glucose (consensus statement). Diabetes Care 2001;24:775-778.
27. Lebovitz HE: Post-prandial hyperglycemic state: importance and consequences. Diabetes Res Clin Pract 1998;40(Suppl):S27-S28.
28. Gurlek A, Erbas T, Gedik O: Frequency of severe hypoglycemia in type 1 and type 2 diabetes during conventional insulin therapy. Exp Clin Endocrinol Diabetes 1999;107:220-224.
29. Klein R, Klein BE, Moss SE, Cruickshanks KJ: The medical management of hyperglycemia over 10-year period in people with diabetes. Diabetes Care 1996;19:744-750.
30. Diabetes Control and Complications Trial Research Group: Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 1997;46:271-286.